Novartis agreed to buy U.S.-based gene therapy company AveXis for $8.7 billion, marking the first big bet by the Swiss pharmaceutical giant’s new chief as he looks to the deal table to refresh his drug-development pipeline.
from WSJ.com: US Business https://ift.tt/2EsSZjz
via IFTTT
No comments:
Post a Comment